Latest Interleukin 2 Stories
Data Support Adoption of Stable Disease as Response Criterion, Raise Intriguing Hypotheses about Sequential Therapy and Utility of IL-2 as Salvage Option CHICAGO, May 31, 2014 /PRNewswire/
Retrospective Analysis Demonstrates Survival Benefits for Patients with Stable and Progressive Disease after HD IL-2 in the Modern Era Suggesting Appropriate Drug Sequencing May Improve Outcomes
New research from the laboratory of Dr. Elizabeth Leadbetter at the Trudeau Institute may lead to a whole new class of vaccines. Dr. Leadbetter's lab has discovered new properties of a potential vaccine adjuvant that suggest it could be useful for enhancing protection against a number of different infections.
SAN DIEGO, Oct. 11 /PRNewswire/ -- More than 120 cancer survivors and caregivers, cancer-treating physicians, and patient advocates gathered in San Diego to share their ProleukinÂ® (aldesleukin for injection) treatment experiences.
In an acute viral infection, most of the white blood cells known as T cells differentiate into cells that fight the virus and die off in the process.
SAN DIEGO, Jan.
- In medieval musical notation, a sign or neume denoting a shake or trill.